MK-3120 for Cancer

Recruiting at 53 trial locations

Overseen By Toll Free Number

Age: 18+

Sex: Any

Trial Phase: Phase 1 & 2

Sponsor: Merck Sharp & Dohme LLC

Must be taking: Antiretrovirals, HBV antivirals

Must not be taking: Immunosuppressives, Systemic anticancer

Disqualifiers: Inflammatory bowel, Cardiovascular, CNS metastases, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

Duration: Up to approximately 18 months

270 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests a new treatment called MK-3120 for individuals with advanced solid tumors, where the cancer has spread and cannot be surgically removed. The main goals are to assess the safety of MK-3120 and its tolerability. Participants will receive varying doses to help researchers understand its effects. This trial suits those with measurable advanced solid tumors who have not found success with other treatments. As a Phase 1 trial, participants will be among the first to receive this treatment, aiding researchers in understanding its effects in humans.

Do I need to stop my current medications for the trial?

The trial information does not specify if you need to stop your current medications. However, if you are on anticancer therapies, you must have stopped them at least 4 weeks before starting the study. It's best to discuss your specific medications with the trial team.

Is there any evidence suggesting that MK-3120 is likely to be safe for humans?

Research has shown that MK-3120 has promising early safety results. In initial studies, patients with advanced solid tumors tolerated it well. Some side effects have been reported, but specific details are not clearly listed in the sources. As this trial is in the early stages, the main goal is to learn more about its safety and patient tolerance. As testing continues, more information will become available. ^{1 2 3 4 5}

Why do researchers think this study treatment might be promising?

Researchers are excited about MK-3120 for cancer because it offers a potentially new approach to treatment. Unlike many current cancer therapies that target rapidly dividing cells indiscriminately, MK-3120 is designed to specifically target cancer cells, minimizing damage to healthy cells. This targeted approach could lead to fewer side effects compared to traditional chemotherapy. Moreover, MK-3120 is being tested at different dose levels, which could help optimize its effectiveness and safety for patients.

What evidence suggests that MK-3120 might be an effective treatment for advanced solid tumors?

Research has shown that MK-3120 may help treat advanced solid tumors. In this trial, participants will receive MK-3120 at different dose levels to evaluate its safety and effectiveness. Studies have found that most patients can take the drug without experiencing severe side effects, indicating a good safety record. Early results suggest it might help shrink or control tumor growth in some patients. Although still in early stages, the drug is designed to specifically target and attack cancer cells. This targeted approach could make it a promising option for people with difficult-to-treat cancers. ^{1 3 6 7 8}

Who Is on the Research Team?

Medical Director

Principal Investigator

Merck Sharp & Dohme LLC

Are You a Good Fit for This Trial?

This trial is for adults with advanced solid tumors that have spread and can't be removed by surgery. Participants must have measurable disease, provide a tumor tissue sample, and have recovered from previous cancer therapy side effects to a manageable level. People with well-controlled HIV on ART, or those who've treated hepatitis B or C are also eligible if they meet certain conditions.

Inclusion Criteria

My advanced cancer can't be removed by surgery and shows on scans.

I have provided a sample of my tumor tissue that has not been treated with radiation.

My side effects from past cancer treatments are mild or gone, except for some hormone issues or mild neuropathy.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive MK-3120 at specified dose levels to evaluate safety and efficacy

Up to approximately 18 months

Follow-up

Participants are monitored for safety and effectiveness after treatment

Up to approximately 54 months

What Are the Treatments Tested in This Trial?

Interventions

• MK-3120

Trial Overview

The study is testing the safety and tolerability of MK-3120 in patients with advanced solid tumors. It aims to find out how well participants handle this potential new treatment option for cancers that occur in body organs and tissues.

How Is the Trial Designed?

Group I: Arm 2 Dose level 2 Experimental Treatment 1 Intervention

Participants receive MK-3120 at dose level 2 as per the schedule specified in the arm.

Group II: Arm 1 Dose level 1 Experimental Treatment 1 Intervention

Participants receive MK-3120 at dose level 1 as per the schedule specified in the arm.

Who Is Running the Clinical Trial?

Merck Sharp & Dohme LLC

Lead Sponsor

Trials

4,096

Recruited

5,232,000+

Chirfi Guindo

Merck Sharp & Dohme LLC

Chief Marketing Officer since 2022

Degree in Engineering from Ecole Centrale de Paris, MBA from New York University Stern School of Business

Robert M. Davis

Merck Sharp & Dohme LLC

Chief Executive Officer since 2021

JD from Northwestern University Pritzker School of Law, MBA from Northwestern University Kellogg Graduate School of Management, Bachelor's in Finance from Miami University

Citations

1.

clinicaltrials.gov

clinicaltrials.gov/study/NCT06818643

A Study to Evaluate the Safety and Efficacy of MK-3120 in ...

Researchers are looking for new ways to treat people with certain advanced solid tumors. Advanced means the cancer has spread to other parts of the body and ...

2.

merckclinicaltrials.com

merckclinicaltrials.com/trial/nct06818643/

A Study to Evaluate the Safety and Efficacy of MK-3120 in ...

Trial Purpose. Researchers are looking for new ways to treat people with certain advanced solid tumors. Advanced means the cancer has spread to other parts of ...

3.

trialfinder.panfoundation.org

trialfinder.panfoundation.org/en-US/trial/listing/574535

A Study to Evaluate the Safety and Efficacy of MK-3120 in ...

A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002) · Overview · Trial locations · Eligibility criteria.

4.

withpower.com

withpower.com/trial/phase-2-neoplasms-malignant-2-2025-ad84c

MK-3120 for Cancer · Recruiting Participants for Phase ...

This trial is for adults with advanced solid tumors that have spread and can't be removed by surgery. Participants must have measurable disease, provide a tumor ...

5.

prezi.com

prezi.com/p/ymqkgozqg_ka/evaluating-mk-3120-in-advanced-solid-tumors/

Evaluating MK-3120 in Advanced Solid Tumors

The study findings indicate that MK-3120 demonstrates a favorable safety profile and potential efficacy in the treatment of advanced solid tumors. Based on ...

6.

msdclinicaltrials.com

msdclinicaltrials.com/trial/nct06818643/

A Study to Evaluate the Safety and Efficacy of MK-3120 in ...

Researchers are looking for new ways to treat people with certain advanced solid tumors. Advanced means the cancer has spread to other parts of the body.

7.

clin.larvol.com

clin.larvol.com/trial-detail/NCT06818643

A Study to Evaluate the Safety and Efficacy of MK-3120 ...

"Has shown promising Phase 1 clinical data. MSD, as the partner, has launched the global Phase 1/2 clinical trial of SKB410.".

8.

trialsummaries.com

trialsummaries.com/Study/StudyDetails?id=26489&tenant=MT_MSD_9011

A Study to Evaluate the Safety and Efficacy of MK-3120 in ...

A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants with Advanced Solid Tumors (MK-3120-002). Trial Identifier: 3120-002. Sponsor: MSD.